Interestingly, a study conducted on MS patients treated with ocrelizumab, an anti-CD20 monoclonal antibody, showed that the depletion of GM-CSF-producing B cells correlates with improved MS course, suggesting their pathogenic role in the disease [159]. The gene discussed is CSF2; the disease is myeloid sarcoma.